

Papua New Guinea support for Measles Rubella vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Papua New Guinea			
2. Grant number: 16-PNG-09a-X			
3. Date of decision letter: 23 November 2015			
4. Date of the partnership framework agreement: 19/11/2013			
5. Programme title: New vaccine support (NVS), Measles second dose Routine			
6. Vaccine type: Measles Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2015 -2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2015	2016	Total ²
Programme budget (US\$)	US\$48,000 ³	US\$145,500	US\$193,500
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015		2016
Number of Measles vaccines doses			358,900
Number of AD syringes			311,000
Number of re-constitution syringes			39,500
Number of safety boxes			3,875
Annual amounts (US\$)	US\$48,000 ⁵		US\$145,500
12. Procurement agency: UNICEF.			
13. Self-procurement: Not applicable.			
14. Co-financing obligations: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

15. Operational support for campaigns: Not applicable																				
<p>16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2016</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>			Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat												
Reports and other information	Due dates																			
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016																			
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat																			
<p>17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>																				
<p>18. Other conditions:</p> <p>Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.</p> <table border="1"> <thead> <tr> <th></th> <th>2016</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of doses of vaccines for Measles Second Dose approved by Gavi.</td> <td>358,900</td> <td>319,000</td> </tr> <tr> <td>Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).</td> <td>\$114,848</td> <td>\$102,080</td> </tr> <tr> <td>Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.</td> <td>188,275</td> <td>167,344</td> </tr> <tr> <td>Number of doses of Measles-Rubella vaccine to be funded by country.</td> <td>170,625</td> <td>151,656</td> </tr> <tr> <td>Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).</td> <td>\$104,081</td> <td>\$92,510</td> </tr> </tbody> </table> <p>Country understands that vaccines will be purchased only after receipt of full payment of the respective amounts due from Country and Gavi by the procurement agency for the number of doses as indicated in this Decision Letter. In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.</p>				2016	2017	Number of doses of vaccines for Measles Second Dose approved by Gavi.	358,900	319,000	Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	\$114,848	\$102,080	Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	188,275	167,344	Number of doses of Measles-Rubella vaccine to be funded by country.	170,625	151,656	Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	\$104,081	\$92,510
	2016	2017																		
Number of doses of vaccines for Measles Second Dose approved by Gavi.	358,900	319,000																		
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	\$114,848	\$102,080																		
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	188,275	167,344																		
Number of doses of Measles-Rubella vaccine to be funded by country.	170,625	151,656																		
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	\$104,081	\$92,510																		

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

23 November 2015

Papua New Guinea support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Papua New Guinea			
2. Grant number: 16-PNG-12c-X			
3. Date of decision letter: 23 November 2015			
4. Date of the partnership framework agreement: 19/11/2013			
5. Programme title: New vaccine support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration⁶: 2013 -2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2013-2015	2016	Total ⁷
Programme budget (US\$)	US\$6,928,239 ⁸	US\$1,186,000	US\$8,114,239
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁹			
Type of supplies to be purchased with Gavi funds in each year	2013-2015	2016	
Number of Pneumococcal vaccines doses		212,400	
Number of AD syringes		210,100	
Number of re-constitution syringes			
Number of safety boxes		2,325	
Annual amounts (US\$)	US\$6,928,239 ¹⁰	US\$1,186,000	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 16-PNG-12c-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	117,000
Number of AD syringes	114,100
Number of re-constitution syringes	
Number of safety boxes	1,275
Value of vaccine doses (US\$)	US\$382,598
Total co-financing payments (US\$) (including freight)	US\$412,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: The Country shall provide the following clarifications to Gavi*:

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: Country is requested to refer to Annex A for the list of actions recommended by the Joint Appraisal and endorsed by the High Level Review Panel. The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

23 November 2015

Papua New Guinea support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Papua New Guinea			
2. Grant number: 16-PNG-04a-X			
3. Date of decision letter: 23 November 2015			
4. Date of the partnership framework agreement: 19/11/2013			
5. Programme title: New vaccine support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme duration¹¹: 2009 -2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2009-2015	2016	Total ¹²
Programme budget (US\$)	US\$10,053,700 ¹³	US\$1,159,500	US\$11,213,200
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ¹⁴			
Type of supplies to be purchased with Gavi funds in each year	2009-2015	2016	
Number of Pentavalent vaccines doses		465,100	
Number of AD syringes		487,600	
Number of re-constitution syringes			
Number of safety boxes		5,400	
Annual amounts (US\$)	US\$10,053,700 ¹⁵	US\$1,159,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹¹ This is the entire duration of the programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the programme.

¹³ This is the consolidated amount for all previous years.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years.

<p>14. Co-financing obligations: Reference code: 16-PNG-04a-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>	
Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	272,200
Number of AD syringes	285,300
Number of re-constitution syringes	
Number of safety boxes	3,150
Value of vaccine doses (US\$)	US\$643,148
Total co-financing payments (US\$) (including freight)	US\$678,500
<p>15. Operational support for campaigns: Not applicable</p>	
<p>16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<p>17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable. <i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>	
<p>18. Other conditions: Country is requested to refer to Annex A for the list of actions recommended by the Joint Appraisal and endorsed by the High Level Review Panel. The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.</p>	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
23 November 2015

ANNEX A

Actions recommended by the Joint Appraisal 2015 and endorsed by the High Level Review Panel:

Actions	Responsibility	Timeline	Potential financial resources needed and source(s) of funding
Supervision & Monitoring	NDOH, WHO, UNICEF	Q3 2015 – Q4 2017	USD 500,000
Update National EPI Policy	NDOH, WHO, UNICEF	Q1-Q4, 2016	USD 40,000
Update Manual for Health Workers on EPI	NDOH, WHO, UNICEF	Q1-Q2, 2015	USD 40,000
Review of EPI Training Manual and development of training/teaching materials	NDOH, WHO, UNICEF	2016 & 2017	USD 350,000
Advocacy, Planning and technical workshop at the provincial level	NDOH, PHA, WHO, UNICEF, DFAT	2016 & 2017	USD 880,000
Data Management and Data Quality Analysis	NDOH, WHO, UNICEF	2016 & 2017	USD 160,000
EVM assessment and completion of cold chain inventory of the country.	NDOH, WHO, UNICEF	Q1-Q2, 2016	USD 60,000
Capacity development of the Health workers and vaccinators at the national, provincial and district level on vaccines, cold chain & logistics management	NDOH, WHO, UNICEF, DFAT	2016 & 2017	USD 440,000
Procure Cold chain equipment	NDOH, GAVI, DFAT, WHO, UNICEF	2016 & 2017	USD 2,000,000
Develop and implementation of Social Mobilization Policy and Plan for PNG	NDOH, UNICEF, WHO	2016 & 2017	USD 500,000
Switch from tOPV to bOPV	NDOH, WHO, UNICEF, GAVI	2016	USD 1,000,000
Piloting of MCH accountability framework in 3 priority provinces in Papua New Guinea	NDOH, WHO, UNICEF	2016-2017	USD 500,000